← Back to home

HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole)

Clinical trials for HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole) explained in plain language.

Never miss a new study

Get alerted when new HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole) trials appear

Sign up with your email to follow new studies for HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Blood test maps hidden resistance signal in advanced breast cancer

Diagnosis Not yet recruiting

People with hormone receptor-positive, HER2-negative advanced breast cancer often start treatment with a CDK4/6 inhibitor plus an aromatase inhibitor. Over time, some tumors develop an ESR1 mutation that can make the aromatase inhibitor stop working. This study takes blood sample…

Matched conditions: HR+/HER2- ABC UNDERGOING 1L TREATMENT WITH CDK4/6I (PALBOCICLIB, ABEMACICLIB OR RIBOCICLIB) AND AI (ANASTROZOLE OR LETROZOLE)

Sponsor: Institut fuer Frauengesundheit • Aim: Diagnosis

Last updated Sep 16, 2026 00:00 UTC

HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole)

Get alerted when new HR+/HER2- abc undergoing 1L treatment with CDK4/6I (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole) trials appear

Blood test maps hidden resistance signal in advanced breast cancer